NCT04686669 - A Relative Bioavailability Study of FOR-6219 in Capsule and Tablet Formulations | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 10, 2020

Primary Completion Date

January 16, 2021

Study Completion Date

January 16, 2021

Conditions

Relative Bioavailability

Interventions

DRUG

FOR-6219 capsule formulation

FOR-6219 capsule formulation will be available as a soft gelatine capsule with a single dose of 50 milligrams, administered orally.

DRUG

FOR-6219 tablet formulation

FOR-6219 tablet formulation will be available as a tablet with a single dose of 50 milligrams, administered orally.

Trial Locations (1)

Richmond Pharmacology Ltd., London